Portfolio news .

Diurnal Group plc

("Diurnal" or the "Company")
 

Notice of Interim Results

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will announce its financial results for the six months ended 31 December 2021 on Tuesday, 22 March 2022.

 
For further information, please visit www.diurnal.co.uk or contact:


Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer



Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

Corporate Broking: Rupert Dearden



Stifel Nicolaus Europe Limited (Joint Corporate Broker)

+44 (0) 20 7710 7600

 Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea, William Palmer-Brown

Corporate Broking: Nick Adams, Nick Harland



FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

Alex Davis



Notes to Editors

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.com.